Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2039
Publisher
MDPI AG
Online
2020-07-24
DOI
10.3390/cancers12082039
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
- (2020) Ali Belkouz et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
- (2020) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line therapies in advanced biliary tract cancers
- (2020) Sri Harsha Tella et al. LANCET ONCOLOGY
- Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
- (2020) Bingqi Ma et al. BMC CANCER
- Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
- (2020) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
- (2020) Cindy Neuzillet et al. INTERNATIONAL JOURNAL OF CANCER
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
- (2020) Jianzhen Lin et al. Hepatobiliary Surgery and Nutrition
- Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
- (2019) Markus Moehler et al. BMC CANCER
- AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
- (2019) Matthew C. H. Ng et al. HEPATOBILIARY SURGERY AND NUTRITION
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
- (2019) Anne Demols et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
- (2019) Aaron C. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR Inhibitors in Advanced Biliary Tract Cancers
- (2019) Chao-En Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
- (2019) Vaibhav Sahai et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).
- (2019) Gilbert Spizzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
- (2019) Florian Moik et al. Scientific Reports
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
- (2019) Maeve A Lowery et al. Lancet Gastroenterology & Hepatology
- Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
- (2019) T. J. Ettrich et al. Scientific Reports
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma
- (2019) Sakti Chakrabarti et al. ONCOLOGIST
- O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
- (2018) F Meric-Bernstam et al. ANNALS OF ONCOLOGY
- Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
- (2018) David K. Lau et al. BRITISH JOURNAL OF CANCER
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
- (2018) R D Kim et al. BRITISH JOURNAL OF CANCER
- A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
- (2018) Yi Zheng et al. BRITISH JOURNAL OF CANCER
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- (2017) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
- (2017) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials
- (2017) Xin Zhuang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. Oncotarget
- Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
- (2017) Sun Young Kim et al. Oncotarget
- Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients (pts) progressing after first-line chemotherapy: A phase II study.
- (2017) R. Buzzoni et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH mutations in cancer and progress toward development of targeted therapeutics
- (2016) L. Dang et al. ANNALS OF ONCOLOGY
- A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
- (2016) John Bridgewater et al. BMC CANCER
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Screening for circulating RAS/RAF mutations by multiplex digital PCR
- (2016) Rikke Fredslund Andersen et al. CLINICA CHIMICA ACTA
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- (2016) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
- (2016) S. K. Saha et al. Cancer Discovery
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
- (2014) A. Santoro et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
- (2014) J. S. Ross et al. ONCOLOGIST
- Characterization of EGFR family gene aberrations in cholangiocarcinoma
- (2014) XIAOQING YANG et al. ONCOLOGY REPORTS
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Mutational landscape of intrahepatic cholangiocarcinoma
- (2014) Shanshan Zou et al. Nature Communications
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
- (2013) Vikram Deshpande et al. BMC CANCER
- Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
- (2013) Yizhou Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature
- (2013) Atuhani S. Burnett et al. JOURNAL OF SURGICAL RESEARCH
- Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
- (2013) Waraporn Chan-on et al. NATURE GENETICS
- Classification, Diagnosis, and Management of Cholangiocarcinoma
- (2012) Nataliya Razumilava et al. Clinical Gastroenterology and Hepatology
- Exome sequencing of liver fluke–associated cholangiocarcinoma
- (2012) Choon Kiat Ong et al. NATURE GENETICS
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
- (2012) Joshua Peck et al. ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Advances in the treatment of metastatic or unresectable biliary tract cancer
- (2010) J. W. Valle ANNALS OF ONCOLOGY
- Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
- (2010) Takashi Sasaki et al. INVESTIGATIONAL NEW DRUGS
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started